VeraBank N.A. Sells 191 Shares of Bristol-Myers Squibb (NYSE:BMY)

VeraBank N.A. lessened its stake in Bristol-Myers Squibb (NYSE:BMY) by 2.9% during the fourth quarter, Holdings Channel reports. The firm owned 6,308 shares of the biopharmaceutical company’s stock after selling 191 shares during the period. VeraBank N.A.’s holdings in Bristol-Myers Squibb were worth $357,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of BMY. Strategic Financial Concepts LLC purchased a new position in Bristol-Myers Squibb during the 4th quarter worth $4,377,000. Allworth Financial LP lifted its position in shares of Bristol-Myers Squibb by 23.1% during the fourth quarter. Allworth Financial LP now owns 77,835 shares of the biopharmaceutical company’s stock valued at $4,444,000 after purchasing an additional 14,624 shares in the last quarter. Principal Securities Inc. boosted its holdings in Bristol-Myers Squibb by 19.2% during the fourth quarter. Principal Securities Inc. now owns 44,800 shares of the biopharmaceutical company’s stock worth $2,534,000 after purchasing an additional 7,204 shares during the last quarter. Centerpoint Advisory Group bought a new stake in Bristol-Myers Squibb in the 4th quarter worth about $284,000. Finally, bLong Financial LLC purchased a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $761,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BMY shares. Leerink Partnrs raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Leerink Partners raised Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and raised their target price for the company from $55.00 to $73.00 in a research report on Tuesday, November 12th. Bank of America reissued a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, December 10th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Finally, Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research note on Friday, February 7th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $57.86.

Bristol-Myers Squibb Stock Performance

NYSE:BMY opened at $53.85 on Friday. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.10. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The stock has a market cap of $109.22 billion, a P/E ratio of -12.18, a PEG ratio of 2.13 and a beta of 0.45. The business’s 50-day moving average price is $57.21 and its two-hundred day moving average price is $54.07.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.81%. As a group, equities analysts predict that Bristol-Myers Squibb will post 6.75 EPS for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Friday, January 3rd were issued a $0.62 dividend. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.61%. The ex-dividend date was Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio is presently -56.11%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.